Secondary analysis of FLOW (type 2 diabetes with CKD, semaglutide vs placebo): the reduction in the primary kidney/cardiovascular death outcome was consistent with or without ASCVD (HR 0.80; 0.74), heart failure (HR 0.67; 0.79) or high CV risk (all P interaction ≥0.40).
Secondary analysisn = 3,533
Tuttle et al. Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses